Latham & Watkins advised AbbVie on the transaction, and Ropes & Gray advised Xilio Therapeutics. Xilio Therapeutics (Nasdaq: XLO) announced a strategic collaboration and option agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Neomorph on the deal. Biotechnology company Neomorph announced a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to develop novel molecular glue...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novo Nordisk in the transaction. IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, announced a strategic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced expanding its collaboration with Valo Health, Inc. (Valo) in a deal worth up to...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised MOMA Therapeutics on the transaction. MOMA Therapeutics announced it has entered into a collaboration and exclusive license agreement with Bayer to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised CAMP4 Therapeutics on the transaction. CAMP4 Therapeutics Corporation, a clinical-stage biotechnology company, announced a research collaboration with BioMarin Pharmaceutical aimed at advancing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Vir Biotechnology in the transaction. Vir Biotechnology (Nasdaq: VIR) announced it has entered into an exclusive worldwide license agreement with Sanofi for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Amylyx Pharmaceuticals in the transaction and Sidley Austin represented Eiger BioPharmaceuticals. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx) announced the acquisition of a...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised FogPharma on the transaction. FogPharma announced a collaboration with ARTBIO Inc. to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform,...
You must be a Standard 1 Year member to access this content.
